Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Now, the landscape of DMD therapy is transforming at a rapid pace ... and many more are in the pipeline,” said session ...

physical therapy, electrotherapy and aquatic therapy. DMD has taken so much away from him, yet despite everything he has ...

Duchenne muscular dystrophy is the most common and most ... "Photobiomodulation, which is widely used in dermatology and orthopedic physical therapy, induces a photochemical process that ...

Patients taking Italfarmaco’s drug also saw a slower decline in physical function over 18 ... which is widely used in DMD therapy assessments. The drug was well-tolerated, with the most common ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy ... measures of physical ability, although ...

Opens in a new tab or window SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences ...

New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores ...

New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores ...

At the heart of Solid Biosciences' value proposition is SGT-003, its lead gene therapy candidate for DMD. The company has reported on-track progress for this therapeutic candidate, with significant ...